Tci Wealth Advisors, Inc. Vir Biotechnology, Inc. Transaction History

Tci Wealth Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	SELL	$22.26 - $30.85 $2,047 - $2,838	-92 Reduced 38.17%	149 $3,000
Q4 2022 Feb 06, 2023	SELL	$19.96 - $28.22 $2,435 - $3,442	-122 Reduced 33.61%	241 $6,000
Q3 2022 Nov 08, 2022	BUY	$18.26 - $31.1 $2,428 - $4,136	133 Added 57.83%	363 $7,000
Q1 2022 Apr 29, 2022	BUY	$21.19 - $40.01 $2,224 - $4,201	105 Added 84.0%	230 $6,000
Q4 2021 Jan 24, 2022	BUY	$30.97 - $54.03 $154 - $270	5 Added 4.17%	125 $5,000
Q3 2021 Oct 29, 2021	BUY	$34.9 - $54.54 $1,989 - $3,108	57 Added 90.48%	120 $5,000
Q2 2021 Aug 02, 2021	BUY	$38.75 - $51.0 $155 - $204	4 Added 6.78%	63 $3,000
Q1 2021 Apr 29, 2021	BUY	$26.34 - $83.07 $1,554 - $4,901	59 New	59 $3,000

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.